Janssen joins Bavarian Nordic to develop HIV, HBV vaccines

Janssen Pharmaceuticals has announced that it is collaborating with Bavarian Nordic to develop vaccines for HIV and hepatitis B virus.

The worldwide exclusive license agreement is aimed at using Bavarian Nordic’s MVA-BN technology and Janssen’s AdVac and DNA-based vaccine technologies to develop the vaccines, according to a Janssen news release.

“We are committed to bringing together the best internal and external science of promising, complementary solutions and advancing them into the clinic as rapidly as possible,” Johan Van Hoof, MD, Janssen Infectious Diseases & Vaccines head of global research and development, said in the release. “Our objective is to identify functional cures for HIV and HBV to control the viruses and prevent potential disease progression without the need for lifelong treatment. With more than 250 million people believed to be living with HBV and 37 million with HIV, it is critical that we address these significant unmet needs.”

The agreement states that Janssen will handle clinical development, registration, commercialization and distribution of the vaccine regimens. Bavarian Nordic will receive an up-front payment and can receive payments for specified development, sales and other milestones, along with tiered royalties on future sales.

In addition, Johnson & Johnson Innovation will make an equity investment in Bavarian Nordic, the Janssen release said.

Disclosure: Van Hoof is employed by Janssen.

Janssen Pharmaceuticals has announced that it is collaborating with Bavarian Nordic to develop vaccines for HIV and hepatitis B virus.

The worldwide exclusive license agreement is aimed at using Bavarian Nordic’s MVA-BN technology and Janssen’s AdVac and DNA-based vaccine technologies to develop the vaccines, according to a Janssen news release.

“We are committed to bringing together the best internal and external science of promising, complementary solutions and advancing them into the clinic as rapidly as possible,” Johan Van Hoof, MD, Janssen Infectious Diseases & Vaccines head of global research and development, said in the release. “Our objective is to identify functional cures for HIV and HBV to control the viruses and prevent potential disease progression without the need for lifelong treatment. With more than 250 million people believed to be living with HBV and 37 million with HIV, it is critical that we address these significant unmet needs.”

The agreement states that Janssen will handle clinical development, registration, commercialization and distribution of the vaccine regimens. Bavarian Nordic will receive an up-front payment and can receive payments for specified development, sales and other milestones, along with tiered royalties on future sales.

In addition, Johnson & Johnson Innovation will make an equity investment in Bavarian Nordic, the Janssen release said.

Disclosure: Van Hoof is employed by Janssen.